星空体育官方入口网站网址大全-登录入口官网

#联合靶向#

18篇内容 | 422人围观

关注话题

话题活跃用户

#插入话题

插入图片

最新最热

[GetTopicListResponse(id=1807722, encodeId=fc1e180e7226c, content=<a href='/topic/show?id=865480e3299' target=_blank style='color:#2F92EE;'>#联合靶向#</a>, objectTitle=Cancers：dMMR/MSI转移性结直肠癌（mCRC)治疗失败后使用传统治疗（CT，化疗联合或不联合靶向治疗）治疗的疗效, objectType=article, longId=294426, objectId=f9a12944260c, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=f9a12944260c, replyNumber=0, likeNumber=59, createdTime=2022-07-12, rootId=0, userName=xiongliangxl, userId=84fb152, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=f9a12944260c, moduleTitle=Cancers：dMMR/MSI转移性结直肠癌（mCRC)治疗失败后使用传统治疗（CT，化疗联合或不联合靶向治疗）治疗的疗效, moduleType=article, hrefUrl=//m.capotfarm.com/article/show_article.do?id=f9a12944260c)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1807720, encodeId=7606180e720db, content=<a href='/topic/show?id=865480e3299' target=_blank style='color:#2F92EE;'>#联合靶向#</a>, objectTitle=共识解读：免疫联合靶向方案为我国晚期肝细胞癌转化治疗开辟新方向！, objectType=article, longId=212517, objectId=e01721251ecb, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=e01721251ecb, replyNumber=0, likeNumber=61, createdTime=2022-05-19, rootId=0, userName=xiongliangxl, userId=84fb152, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=e01721251ecb, moduleTitle=共识解读：免疫联合靶向方案为我国晚期肝细胞癌转化治疗开辟新方向！, moduleType=article, hrefUrl=//m.capotfarm.com/article/show_article.do?id=e01721251ecb)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1807721, encodeId=92d5180e721f7, content=<a href='/topic/show?id=865480e3299' target=_blank style='color:#2F92EE;'>#联合靶向#</a>, objectTitle=免疫联合靶向方案用于肝癌转化治疗专家共识发布，助力肝癌治疗突破, objectType=article, longId=213677, objectId=e6b52136e7d0, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=e6b52136e7d0, replyNumber=0, likeNumber=54, createdTime=2021-12-22, rootId=0, userName=xiongliangxl, userId=84fb152, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=e6b52136e7d0, moduleTitle=免疫联合靶向方案用于肝癌转化治疗专家共识发布，助力肝癌治疗突破, moduleType=article, hrefUrl=//m.capotfarm.com/article/show_article.do?id=e6b52136e7d0)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1807718, encodeId=7d2c180e71894, content=<a href='/topic/show?id=865480e3299' target=_blank style='color:#2F92EE;'>#联合靶向#</a>, objectTitle=ASCO GU 2021: 免疫联合靶向在晚期肾癌中大获成功，完成2年治疗的人群结果公布（KEYNOTE-426研究）, objectType=article, longId=207203, objectId=134820e203ba, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=134820e203ba, replyNumber=0, likeNumber=50, createdTime=2021-05-06, rootId=0, userName=xiongliangxl, userId=84fb152, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=134820e203ba, moduleTitle=ASCO GU 2021: 免疫联合靶向在晚期肾癌中大获成功，完成2年治疗的人群结果公布（KEYNOTE-426研究）, moduleType=article, hrefUrl=//m.capotfarm.com/article/show_article.do?id=134820e203ba)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1807719, encodeId=6fb0180e7194d, content=<a href='/topic/show?id=865480e3299' target=_blank style='color:#2F92EE;'>#联合靶向#</a>, objectTitle=Nat Med：Durvalumab联合靶向疗法治疗晚期尿路上皮癌, objectType=article, longId=210828, objectId=32fc21082884, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=32fc21082884, replyNumber=0, likeNumber=57, createdTime=2021-12-31, rootId=0, userName=xiongliangxl, userId=84fb152, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=32fc21082884, moduleTitle=Nat Med：Durvalumab联合靶向疗法治疗晚期尿路上皮癌, moduleType=article, hrefUrl=//m.capotfarm.com/article/show_article.do?id=32fc21082884)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1807717, encodeId=68ac180e71799, content=<a href='/topic/show?id=865480e3299' target=_blank style='color:#2F92EE;'>#联合靶向#</a>, objectTitle=罗氏PD-L1单抗Tecentriq联合靶向疗法：获FDA批准治疗晚期黑色素瘤, objectType=article, longId=198563, objectId=ec5d198563ab, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=ec5d198563ab, replyNumber=0, likeNumber=52, createdTime=2020-11-10, rootId=0, userName=xiongliangxl, userId=84fb152, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=ec5d198563ab, moduleTitle=罗氏PD-L1单抗Tecentriq联合靶向疗法：获FDA批准治疗晚期黑色素瘤, moduleType=article, hrefUrl=//m.capotfarm.com/article/show_article.do?id=ec5d198563ab)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1807713, encodeId=683b180e71368, content=<a href='/topic/show?id=865480e3299' target=_blank style='color:#2F92EE;'>#联合靶向#</a>, objectTitle=MSS型肠癌免疫联合靶向探索——从作用机制到临床研究, objectType=article, longId=175803, objectId=70981e5803a6, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=70981e5803a6, replyNumber=0, likeNumber=66, createdTime=2020-01-25, rootId=0, userName=xiongliangxl, userId=84fb152, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=70981e5803a6, moduleTitle=MSS型肠癌免疫联合靶向探索——从作用机制到临床研究, moduleType=article, hrefUrl=//m.capotfarm.com/article/show_article.do?id=70981e5803a6)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1807716, encodeId=e716180e71612, content=<a href='/topic/show?id=865480e3299' target=_blank style='color:#2F92EE;'>#联合靶向#</a>, objectTitle=病例：联合靶向和局部治疗用于Ⅲb期肝癌患者，展现出良好效果, objectType=article, longId=183980, objectId=27ae18398071, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=27ae18398071, replyNumber=0, likeNumber=52, createdTime=2020-09-09, rootId=0, userName=xiongliangxl, userId=84fb152, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=27ae18398071, moduleTitle=病例：联合靶向和局部治疗用于Ⅲb期肝癌患者，展现出良好效果, moduleType=article, hrefUrl=//m.capotfarm.com/article/show_article.do?id=27ae18398071)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1807714, encodeId=f420180e7143f, content=<a href='/topic/show?id=865480e3299' target=_blank style='color:#2F92EE;'>#联合靶向#</a>, objectTitle=MSS型肠癌免疫联合靶向探索——前路坎坷，曙光微现, objectType=article, longId=176062, objectId=7c361e6062b2, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=7c361e6062b2, replyNumber=0, likeNumber=59, createdTime=2019-12-01, rootId=0, userName=xiongliangxl, userId=84fb152, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=7c361e6062b2, moduleTitle=MSS型肠癌免疫联合靶向探索——前路坎坷，曙光微现, moduleType=article, hrefUrl=//m.capotfarm.com/article/show_article.do?id=7c361e6062b2)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1807712, encodeId=1fc2180e71238, content=<a href='/topic/show?id=865480e3299' target=_blank style='color:#2F92EE;'>#联合靶向#</a>, objectTitle=局部联合靶向，仑伐替尼为肝癌综合治疗添利器, objectType=article, longId=164715, objectId=b31d164e155b, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=b31d164e155b, replyNumber=0, likeNumber=54, createdTime=2019-08-12, rootId=0, userName=xiongliangxl, userId=84fb152, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=b31d164e155b, moduleTitle=局部联合靶向，仑伐替尼为肝癌综合治疗添利器, moduleType=article, hrefUrl=//m.capotfarm.com/article/show_article.do?id=b31d164e155b)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1807715, encodeId=0332180e7157e, content=<a href='/topic/show?id=865480e3299' target=_blank style='color:#2F92EE;'>#联合靶向#</a>, objectTitle=MSS型肠癌免疫联合靶向探索——解析成功与失败的原因, objectType=article, longId=177140, objectId=5d501e714024, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=5d501e714024, replyNumber=0, likeNumber=62, createdTime=2019-10-23, rootId=0, userName=xiongliangxl, userId=84fb152, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=5d501e714024, moduleTitle=MSS型肠癌免疫联合靶向探索——解析成功与失败的原因, moduleType=article, hrefUrl=//m.capotfarm.com/article/show_article.do?id=5d501e714024)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1807711, encodeId=c071180e71101, content=<a href='/topic/show?id=865480e3299' target=_blank style='color:#2F92EE;'>#联合靶向#</a>, objectTitle=Blood：Obinutuzumab、依鲁替尼和venetoclax联合靶向疗法用于慢性淋巴细胞白血病的1b期研究结果, objectType=article, longId=146853, objectId=ab0514685311, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=ab0514685311, replyNumber=0, likeNumber=71, createdTime=2019-02-12, rootId=0, userName=xiongliangxl, userId=84fb152, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=ab0514685311, moduleTitle=Blood：Obinutuzumab、依鲁替尼和venetoclax联合靶向疗法用于慢性淋巴细胞白血病的1b期研究结果, moduleType=article, hrefUrl=//m.capotfarm.com/article/show_article.do?id=ab0514685311)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1807709, encodeId=5e3a180e70987, content=<a href='/topic/show?id=865480e3299' target=_blank style='color:#2F92EE;'>#联合靶向#</a>, objectTitle=联合靶向BRAF和HSP90的药物显示了黑素瘤治疗潜能, objectType=article, longId=136724, objectId=5b79136e249e, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=5b79136e249e, replyNumber=0, likeNumber=62, createdTime=2018-09-03, rootId=0, userName=xiongliangxl, userId=84fb152, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=5b79136e249e, moduleTitle=联合靶向BRAF和HSP90的药物显示了黑素瘤治疗潜能, moduleType=article, hrefUrl=//m.capotfarm.com/article/show_article.do?id=5b79136e249e)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1807710, encodeId=e7cf180e71052, content=<a href='/topic/show?id=865480e3299' target=_blank style='color:#2F92EE;'>#联合靶向#</a>, objectTitle=诺华BRAF抑制剂与MEK抑制剂获FDA批准联合靶向治疗黑色素瘤, objectType=article, longId=137007, objectId=d64a13e007c3, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=d64a13e007c3, replyNumber=0, likeNumber=69, createdTime=2018-05-17, rootId=0, userName=xiongliangxl, userId=84fb152, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=d64a13e007c3, moduleTitle=诺华BRAF抑制剂与MEK抑制剂获FDA批准联合靶向治疗黑色素瘤, moduleType=article, hrefUrl=//m.capotfarm.com/article/show_article.do?id=d64a13e007c3)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1807708, encodeId=848d180e7084a, content=<a href='/topic/show?id=865480e3299' target=_blank style='color:#2F92EE;'>#联合靶向#</a>, objectTitle=乳腺癌内分泌治疗1+1时代：内分泌联合靶向精准克服耐药, objectType=article, longId=126100, objectId=040012610029, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=040012610029, replyNumber=0, likeNumber=61, createdTime=2018-05-03, rootId=0, userName=xiongliangxl, userId=84fb152, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=040012610029, moduleTitle=乳腺癌内分泌治疗1+1时代：内分泌联合靶向精准克服耐药, moduleType=article, hrefUrl=//m.capotfarm.com/article/show_article.do?id=040012610029)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1807707, encodeId=dcfd180e707c4, content=<a href='/topic/show?id=865480e3299' target=_blank style='color:#2F92EE;'>#联合靶向#</a>, objectTitle=ASCO 2014：吴小华谈复发卵巢癌联合靶向治疗试验, objectType=article, longId=35714, objectId=b98435e1424, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=b98435e1424, replyNumber=0, likeNumber=63, createdTime=2015-05-08, rootId=0, userName=xiongliangxl, userId=84fb152, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=b98435e1424, moduleTitle=ASCO 2014：吴小华谈复发卵巢癌联合靶向治疗试验, moduleType=article, hrefUrl=//m.capotfarm.com/article/show_article.do?id=b98435e1424)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1807706, encodeId=767f180e706b4, content=<a href='/topic/show?id=865480e3299' target=_blank style='color:#2F92EE;'>#联合靶向#</a>, objectTitle=eLife: 生物信息学显示两药联合靶向抗癌可能提高疗效, objectType=article, longId=21917, objectId=0ec32191e4a, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=0ec32191e4a, replyNumber=0, likeNumber=49, createdTime=2013-10-16, rootId=0, userName=xiongliangxl, userId=84fb152, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=0ec32191e4a, moduleTitle=eLife: 生物信息学显示两药联合靶向抗癌可能提高疗效, moduleType=article, hrefUrl=//m.capotfarm.com/article/show_article.do?id=0ec32191e4a)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1807705, encodeId=07b2180e705fd, content=<a href='/topic/show?id=865480e3299' target=_blank style='color:#2F92EE;'>#联合靶向#</a>, objectTitle=AI+mTOR抑制剂内分泌联合靶向治疗乳腺癌的又一尝试, objectType=article, longId=3778, objectId=a4a63e781d, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=a4a63e781d, replyNumber=0, likeNumber=54, createdTime=2012-05-07, rootId=0, userName=xiongliangxl, userId=84fb152, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=a4a63e781d, moduleTitle=AI+mTOR抑制剂内分泌联合靶向治疗乳腺癌的又一尝试, moduleType=article, hrefUrl=//m.capotfarm.com/article/show_article.do?id=a4a63e781d)], followStatus=false, userIsMember=false, type=1, lengthMark=0)] 梅斯话题小助手

联合靶向

2020-05-29

xiongliangxl (审核中...)

前往app查看评论内容

#联合靶向#

Cancers：dMMR/MSI转移性结直肠癌（mCRC)治疗失败后使用传统治疗（CT，化疗联合或不联合靶向治疗）治疗的疗效

2022-07-12

xiongliangxl (审核中...)

前往app查看评论内容

#联合靶向#

共识解读：免疫联合靶向方案为我国晚期肝细胞癌转化治疗开辟新方向！

2022-05-19

xiongliangxl (审核中...)

前往app查看评论内容

#联合靶向#

免疫联合靶向方案用于肝癌转化治疗专家共识发布，助力肝癌治疗突破

2021-12-22

xiongliangxl (审核中...)

前往app查看评论内容

#联合靶向#

ASCO GU 2021: 免疫联合靶向在晚期肾癌中大获成功，完成2年治疗的人群结果公布（KEYNOTE-426研究）

2021-05-06

xiongliangxl (审核中...)

前往app查看评论内容

#联合靶向#

Nat Med：Durvalumab联合靶向疗法治疗晚期尿路上皮癌

2021-12-31

xiongliangxl (审核中...)

前往app查看评论内容

#联合靶向#

罗氏PD-L1单抗Tecentriq联合靶向疗法：获FDA批准治疗晚期黑色素瘤

2020-11-10

xiongliangxl (审核中...)

前往app查看评论内容

#联合靶向#

MSS型肠癌免疫联合靶向探索——从作用机制到临床研究

2020-01-25

xiongliangxl (审核中...)

前往app查看评论内容

#联合靶向#

病例：联合靶向和局部治疗用于Ⅲb期肝癌患者，展现出良好效果

2020-09-09

xiongliangxl (审核中...)

前往app查看评论内容

#联合靶向#

MSS型肠癌免疫联合靶向探索——前路坎坷，曙光微现

2019-12-01

xiongliangxl (审核中...)

前往app查看评论内容

#联合靶向#

局部联合靶向，仑伐替尼为肝癌综合治疗添利器

2019-08-12

xiongliangxl (审核中...)

前往app查看评论内容

#联合靶向#

MSS型肠癌免疫联合靶向探索——解析成功与失败的原因

2019-10-23

xiongliangxl (审核中...)

前往app查看评论内容

#联合靶向#

Blood：Obinutuzumab、依鲁替尼和venetoclax联合靶向疗法用于慢性淋巴细胞白血病的1b期研究结果

2019-02-12

xiongliangxl (审核中...)

前往app查看评论内容

#联合靶向#

联合靶向BRAF和HSP90的药物显示了黑素瘤治疗潜能

2018-09-03

xiongliangxl (审核中...)

前往app查看评论内容

#联合靶向#

诺华BRAF抑制剂与MEK抑制剂获FDA批准联合靶向治疗黑色素瘤

2018-05-17

xiongliangxl (审核中...)

前往app查看评论内容

#联合靶向#

乳腺癌内分泌治疗1+1时代：内分泌联合靶向精准克服耐药

2018-05-03

xiongliangxl (审核中...)

前往app查看评论内容

#联合靶向#

ASCO 2014：吴小华谈复发卵巢癌联合靶向治疗试验

2015-05-08

xiongliangxl (审核中...)

前往app查看评论内容

#联合靶向#

eLife: 生物信息学显示两药联合靶向抗癌可能提高疗效

2013-10-16

xiongliangxl (审核中...)

前往app查看评论内容

#联合靶向#

AI+mTOR抑制剂内分泌联合靶向治疗乳腺癌的又一尝试

2012-05-07

科室
- - 订阅+
  - 更多科室
工具
服务